Table 1 Data from the Marseille cohort
From: Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome
All patients | Patients with normal platelets count | Patients with thrombocytopenia | p | |
|---|---|---|---|---|
Number of patients | 43 | 6 | 37 | |
Number of episodes | 56 | 10 | 46 | |
Number of relapsing patients | 10 | 3 | 7 | 0.88 |
Sex (%male) | 40% | 17% | 43% | 0.40 |
Age (years) | 45 [25–64] | 40 [32–50] | 44 [23–66] | 0.78 |
Biopsy proven TMA | 10 (23%) | 3 (50%) | 7 (19%) | 0.38 |
Etiology identification | 24 (56%) | 3 (50%) | 21 (57%) | |
Identified mutation | 6 | 2 | 4 | |
Anti-factor H Autoantibody | 1 | 1 | ||
Toxic | 5 | 1 | 4 | |
Cancer associated | 2 | 2 | ||
Graft associated | 2 | 1 | ||
Autoimmune disease | 3 | 3 | ||
Shiga like toxin | 4 | 4 | ||
Post infectious disease | 2 | 2 | ||
Potential explanation | 10 (23%) | 2 (33%) | 8 (22.5%) | |
Familial form | 2 | 2 | ||
Recurrent form | 4 | 2 | 2 | |
Associated with low C3 | 4 | 4 | ||
Idiopathic | 9 (21%) | 1 (17%) | 8 (22.5%) | |
Pregnancy associated HUS | 3 (11,5%) | 2 (40%) | 1 (5%) | 0.151 |
Platelets (G/L)* | 66 [55–108] | 234 [183–265] | 53 [27–88] | < 0.001 |
Hb (g/dl) | 7.6 [7.1-8.9] | 8 [7.2-9.8] | 7.7 [7.1-8.8] | 0.38 |
LDH* (UI/L) | 1012 [607–202] | 612 [400–705] | 1074 [659–2192] | 0.012 |
Haptoglobin | 0 [0–0] | 0 [0–0,28] | 0 [0–0] | 0.064 |
Schizocytes %* | 2.2 [1.5-3.8] | 0.8 [0–2] | 3 [1.5-4.4] | < 0.001 |
Creatinine (mg/dl) | 3.4 [2.4-5.5] | 2.5 [1.4-5.3] | 3.5 [2.5-5.6] | 0.76 |
Proteinuria (g/24h) | 2.2 [1.1 – 3.6] | 1.5 [0.8 – 2.3] | 2.32 [1.2 – 4] | 0.15 |
HD at the diagnosis | 12 (21%) | 2 (20%) | 10 (22%) | 0.68 |
HD during the episode | 34 (61%) | 5 (50%) | 29 (63%) | 0,6 |
Death (%) | 1 (2%) | 1 (17%) | 0 (0%) | 0,6 |
Plasmatherapy | ||||
Number of episodes treated | 52 (93%) | 8 (80%) | 44 (96%) | 0.88 |
Number of plasmatherapy sessions | 15 [12–18] | 15 [6–16.5] | 14 [12–20] |